Adam A. Nabeebaccus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam A. Nabeebaccus has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Ajay M. Shah
King's College London
4 shared publications Ajay M. Shah
BHF Centre of Excellence King's College London, The James Black Centre, 125 Coldharbour Lane, London, SE5 9NU, UK
1 shared publicationAjay Shah
Cardiovascular Division, King's College London, London, UK
1 shared publication- Alexandros Papachristidis
Department of Cardiology, King’s College Hospital , Denmark Hill, London SE5 9RS
1 shared publication Alison Brewer
Cardiovascular Division, King's College London, London, UK
1 shared publication- Ana Pericao
Guy’s and St Thomas’ Hospital, London, United Kingdom (C.C., O.D., N.D., D.P., A. Pericao, M.R., H.S., V.S., K.V., L. Faconti, G.C.-W.).
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100608
Heart failure with preserved ejection fraction (HFpEF): Diagnosis and management for the general physician
- 22 June 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100608
Open AccessHeart failure with preserved ejection fraction (HFpEF): Diagnosis and management for the general physician
- Open Access
- 24 March 2022
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 118 (17) , 3305-3319
The regulation of cardiac intermediary metabolism by NADPH oxidases
NADPH oxidases (NOXs), enzymes whose primary function is to generate reactive oxygen species, are important regulators of the heart’s physiological function and response to pathological insults. The role of NOX-driven redox signalling in pathophysiological myocardial remodelling, including processes such as interstitial fibrosis, contractile dysfunction, cellular hypertrophy, and cell survival, is well recognized. While the NOX2 isoform promotes many detrimental effects, the NOX4 isoform has attracted considerable attention as a driver of adaptive stress responses both during pathology and under physiological states such as exercise. Recent studies have begun to define some of the NOX4-modulated mechanisms that may underlie these adaptive responses. In particular, novel functions of NOX4 in driving cellular metabolic changes have emerged. Alterations in cellular metabolism are a recognized hallmark of the heart’s response to physiological and pathological stresses. In this review, we highlight the emerging roles of NOX enzymes as important modulators of cellular intermediary metabolism in the heart, linking stress responses not only to myocardial energetics but also other functions. The novel interplay of NOX-modulated redox signalling pathways and intermediary metabolism in the heart is unravelling a new aspect of the fascinating biology of these enzymes which will inform a better understanding of how they drive adaptive responses. We also discuss the implications of these new findings for therapeutic approaches that target metabolism in cardiac disease.
- 24 March 2022
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 118 (17) , 3305-3319
Open AccessThe regulation of cardiac intermediary metabolism by NADPH oxidases
NADPH oxidases (NOXs), enzymes whose primary function is to generate reactive oxygen species, are important regulators of the heart’s physiological function and response to pathological insults. The role of NOX-driven redox signalling in pathophysiological myocardial remodelling, including processes such as interstitial fibrosis, contractile dysfunction, cellular hypertrophy, and cell survival, is well recognized. While the NOX2 isoform promotes many detrimental effects, the NOX4 isoform has attracted considerable attention as a driver of adaptive stress responses both during pathology and under physiological states such as exercise. Recent studies have begun to define some of the NOX4-modulated mechanisms that may underlie these adaptive responses. In particular, novel functions of NOX4 in driving cellular metabolic changes have emerged. Alterations in cellular metabolism are a recognized hallmark of the heart’s response to physiological and pathological stresses. In this review, we highlight the emerging roles of NOX enzymes as important modulators of cellular intermediary metabolism in the heart, linking stress responses not only to myocardial energetics but also other functions. The novel interplay of NOX-modulated redox signalling pathways and intermediary metabolism in the heart is unravelling a new aspect of the fascinating biology of these enzymes which will inform a better understanding of how they drive adaptive responses. We also discuss the implications of these new findings for therapeutic approaches that target metabolism in cardiac disease.
- Open Access
- 1 December 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 583, 121-127
Cardiomyocyte protein O-GlcNAcylation is regulated by GFAT1 not GFAT2
- 1 December 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 583, 121-127
Open AccessCardiomyocyte protein O-GlcNAcylation is regulated by GFAT1 not GFAT2
- 1 June 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 77 (6) , 2014-2022
First-Phase Ejection Fraction, a Measure of Preclinical Heart Failure, Is Strongly Associated With Increased Mortality in Patients With COVID-19
Presence of heart failure is associated with a poor prognosis in patients with coronavirus disease 2019 (COVID-19). The aim of the present study was to examine whether first-phase ejection fraction (EF1), the ejection fraction measured in early systole up to the time of peak aortic velocity, a sensitive measure of preclinical heart failure, is associated with survival in patients hospitalized with COVID-19. A retrospective outcome study was performed in patients hospitalized with COVID-19 who underwent echocardiography (n=380) at the West Branch of the Union Hospital, Wuhan, China and in patients admitted to King’s Health Partners in South London, United Kingdom. Association of EF1 with survival was performed using Cox proportional hazards regression. EF1 was compared in patients with COVID-19 and in historical controls with similar comorbidities (n=266) who had undergone echocardiography before the COVID-19 pandemic. In patients with COVID-19, EF1 was a strong predictor of survival in each patient group (Wuhan and London). In the combined group, EF1 was a stronger predictor of survival than other clinical, laboratory, and echocardiographic characteristics including age, comorbidities, and biochemical markers. A cutoff value of 25% for EF1 gave a hazard ratio of 5.23 ([95% CI, 2.85–9.60]; PPP=0.092, adjusted for prevalence of risk factors and comorbidities). Impaired EF1 is strongly associated with mortality in COVID-19 and probably reflects preexisting, preclinical heart failure.
- 1 June 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 77 (6) , 2014-2022
First-Phase Ejection Fraction, a Measure of Preclinical Heart Failure, Is Strongly Associated With Increased Mortality in Patients With COVID-19
Presence of heart failure is associated with a poor prognosis in patients with coronavirus disease 2019 (COVID-19). The aim of the present study was to examine whether first-phase ejection fraction (EF1), the ejection fraction measured in early systole up to the time of peak aortic velocity, a sensitive measure of preclinical heart failure, is associated with survival in patients hospitalized with COVID-19. A retrospective outcome study was performed in patients hospitalized with COVID-19 who underwent echocardiography (n=380) at the West Branch of the Union Hospital, Wuhan, China and in patients admitted to King’s Health Partners in South London, United Kingdom. Association of EF1 with survival was performed using Cox proportional hazards regression. EF1 was compared in patients with COVID-19 and in historical controls with similar comorbidities (n=266) who had undergone echocardiography before the COVID-19 pandemic. In patients with COVID-19, EF1 was a strong predictor of survival in each patient group (Wuhan and London). In the combined group, EF1 was a stronger predictor of survival than other clinical, laboratory, and echocardiographic characteristics including age, comorbidities, and biochemical markers. A cutoff value of 25% for EF1 gave a hazard ratio of 5.23 ([95% CI, 2.85–9.60]; PPP=0.092, adjusted for prevalence of risk factors and comorbidities). Impaired EF1 is strongly associated with mortality in COVID-19 and probably reflects preexisting, preclinical heart failure.
- Open Access
- 27 December 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise
Regular exercise has widespread health benefits. Fundamental to these beneficial effects is the ability of the heart to intermittently and substantially increase its performance without incurring damage, but the underlying homeostatic mechanisms are unclear. We identify the ROS-generating NADPH oxidase-4 (Nox4) as an essential regulator of exercise performance in mice. Myocardial Nox4 levels increase during acute exercise and trigger activation of the transcription factor Nrf2, with the induction of multiple endogenous antioxidants. Cardiomyocyte-specific Nox4-deficient (csNox4KO) mice display a loss of exercise-induced Nrf2 activation, cardiac oxidative stress and reduced exercise performance. Cardiomyocyte-specific Nrf2-deficient (csNrf2KO) mice exhibit similar compromised exercise capacity, with mitochondrial and cardiac dysfunction. Supplementation with an Nrf2 activator or a mitochondria-targeted antioxidant effectively restores cardiac performance and exercise capacity in csNox4KO and csNrf2KO mice respectively. The Nox4/Nrf2 axis therefore drives a hormetic response that is required for optimal cardiac mitochondrial and contractile function during physiological exercise.
- 27 December 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Open AccessMyocardial NADPH oxidase-4 regulates the physiological response to acute exercise
Regular exercise has widespread health benefits. Fundamental to these beneficial effects is the ability of the heart to intermittently and substantially increase its performance without incurring damage, but the underlying homeostatic mechanisms are unclear. We identify the ROS-generating NADPH oxidase-4 (Nox4) as an essential regulator of exercise performance in mice. Myocardial Nox4 levels increase during acute exercise and trigger activation of the transcription factor Nrf2, with the induction of multiple endogenous antioxidants. Cardiomyocyte-specific Nox4-deficient (csNox4KO) mice display a loss of exercise-induced Nrf2 activation, cardiac oxidative stress and reduced exercise performance. Cardiomyocyte-specific Nrf2-deficient (csNrf2KO) mice exhibit similar compromised exercise capacity, with mitochondrial and cardiac dysfunction. Supplementation with an Nrf2 activator or a mitochondria-targeted antioxidant effectively restores cardiac performance and exercise capacity in csNox4KO and csNrf2KO mice respectively. The Nox4/Nrf2 axis therefore drives a hormetic response that is required for optimal cardiac mitochondrial and contractile function during physiological exercise.
- Open Access
- 1 December 2018
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 3 (6) , 810-812
Hydrogen Sulfide Therapy Promotes Beneficial Systemic Effects in Experimental Heart Failure
- 1 December 2018
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 3 (6) , 810-812
Open AccessHydrogen Sulfide Therapy Promotes Beneficial Systemic Effects in Experimental Heart Failure
- 1 February 2015
- Published by Elsevier in The Lancet
- Vol. 385, S73
Cardiac-targeted NADPH oxidase 4 in the adaptive cardiac remodelling of the murine heart
- 1 February 2015
- Published by Elsevier in The Lancet
- Vol. 385, S73
Cardiac-targeted NADPH oxidase 4 in the adaptive cardiac remodelling of the murine heart